Safety of L-proline as a stabilizer for immunoglobulin products

John B. Hagan, Richard L. Wasserman, Jeffrey S. Baggish, Martin O. Spycher, Melvin Berger, Vandana Shashi, Emanuel Lohrmann, Kathleen E. Sullivan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Privigen ® (immune globulin intravenous [human], 10% liquid) and Hizentra ® (immune globulin subcutaneous [human], 20% liquid) are stabilized by proline. The clinical implications of administering proline-containing immunoglobulin products to patients with defects of proline metabolism have not been addressed; Privigen and Hizentra are contraindicated in these patients. Some patients with chromosome 22q11.2 deletion syndrome have elevated proline levels; however, only 3-4% of patients also have an immunodeficiency that requires IgG therapy. This review summarizes the evidence related to the safety and pharmacokinetics of proline assessed in Privigen and Hizentra preclinical and clinical studies, and subsequent implications for patients with defects in proline metabolism. Clinical data indicate that proline does not accumulate after Privigen or Hizentra treatment and is not associated with adverse events. There is no evidence to suggest that patients with defects of proline metabolism would be affected by transient elevations in plasma proline following Privigen and/or Hizentra treatment.

Original languageEnglish (US)
Pages (from-to)169-178
Number of pages10
JournalExpert Review of Clinical Immunology
Volume8
Issue number2
DOIs
StatePublished - Feb 2012

Fingerprint

Proline
Immunoglobulins
Intravenous Immunoglobulins
Safety
DiGeorge Syndrome
Chromosome Deletion
Therapeutics
Pharmacokinetics
Immunoglobulin G
Hizentra

Keywords

  • 22q11.2 deletion syndrome
  • hyperprolinemia
  • intravenous immunoglobulin
  • pharmacokinetics
  • proline
  • proline metabolism
  • safety
  • subcutaneous immunoglobulin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Hagan, J. B., Wasserman, R. L., Baggish, J. S., Spycher, M. O., Berger, M., Shashi, V., ... Sullivan, K. E. (2012). Safety of L-proline as a stabilizer for immunoglobulin products. Expert Review of Clinical Immunology, 8(2), 169-178. https://doi.org/10.1586/eci.11.97

Safety of L-proline as a stabilizer for immunoglobulin products. / Hagan, John B.; Wasserman, Richard L.; Baggish, Jeffrey S.; Spycher, Martin O.; Berger, Melvin; Shashi, Vandana; Lohrmann, Emanuel; Sullivan, Kathleen E.

In: Expert Review of Clinical Immunology, Vol. 8, No. 2, 02.2012, p. 169-178.

Research output: Contribution to journalArticle

Hagan, JB, Wasserman, RL, Baggish, JS, Spycher, MO, Berger, M, Shashi, V, Lohrmann, E & Sullivan, KE 2012, 'Safety of L-proline as a stabilizer for immunoglobulin products', Expert Review of Clinical Immunology, vol. 8, no. 2, pp. 169-178. https://doi.org/10.1586/eci.11.97
Hagan JB, Wasserman RL, Baggish JS, Spycher MO, Berger M, Shashi V et al. Safety of L-proline as a stabilizer for immunoglobulin products. Expert Review of Clinical Immunology. 2012 Feb;8(2):169-178. https://doi.org/10.1586/eci.11.97
Hagan, John B. ; Wasserman, Richard L. ; Baggish, Jeffrey S. ; Spycher, Martin O. ; Berger, Melvin ; Shashi, Vandana ; Lohrmann, Emanuel ; Sullivan, Kathleen E. / Safety of L-proline as a stabilizer for immunoglobulin products. In: Expert Review of Clinical Immunology. 2012 ; Vol. 8, No. 2. pp. 169-178.
@article{96a9f3fef52e41ed996627288e5b1240,
title = "Safety of L-proline as a stabilizer for immunoglobulin products",
abstract = "Privigen {\circledR} (immune globulin intravenous [human], 10{\%} liquid) and Hizentra {\circledR} (immune globulin subcutaneous [human], 20{\%} liquid) are stabilized by proline. The clinical implications of administering proline-containing immunoglobulin products to patients with defects of proline metabolism have not been addressed; Privigen and Hizentra are contraindicated in these patients. Some patients with chromosome 22q11.2 deletion syndrome have elevated proline levels; however, only 3-4{\%} of patients also have an immunodeficiency that requires IgG therapy. This review summarizes the evidence related to the safety and pharmacokinetics of proline assessed in Privigen and Hizentra preclinical and clinical studies, and subsequent implications for patients with defects in proline metabolism. Clinical data indicate that proline does not accumulate after Privigen or Hizentra treatment and is not associated with adverse events. There is no evidence to suggest that patients with defects of proline metabolism would be affected by transient elevations in plasma proline following Privigen and/or Hizentra treatment.",
keywords = "22q11.2 deletion syndrome, hyperprolinemia, intravenous immunoglobulin, pharmacokinetics, proline, proline metabolism, safety, subcutaneous immunoglobulin",
author = "Hagan, {John B.} and Wasserman, {Richard L.} and Baggish, {Jeffrey S.} and Spycher, {Martin O.} and Melvin Berger and Vandana Shashi and Emanuel Lohrmann and Sullivan, {Kathleen E.}",
year = "2012",
month = "2",
doi = "10.1586/eci.11.97",
language = "English (US)",
volume = "8",
pages = "169--178",
journal = "Expert Review of Clinical Immunology",
issn = "1744-666X",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Safety of L-proline as a stabilizer for immunoglobulin products

AU - Hagan, John B.

AU - Wasserman, Richard L.

AU - Baggish, Jeffrey S.

AU - Spycher, Martin O.

AU - Berger, Melvin

AU - Shashi, Vandana

AU - Lohrmann, Emanuel

AU - Sullivan, Kathleen E.

PY - 2012/2

Y1 - 2012/2

N2 - Privigen ® (immune globulin intravenous [human], 10% liquid) and Hizentra ® (immune globulin subcutaneous [human], 20% liquid) are stabilized by proline. The clinical implications of administering proline-containing immunoglobulin products to patients with defects of proline metabolism have not been addressed; Privigen and Hizentra are contraindicated in these patients. Some patients with chromosome 22q11.2 deletion syndrome have elevated proline levels; however, only 3-4% of patients also have an immunodeficiency that requires IgG therapy. This review summarizes the evidence related to the safety and pharmacokinetics of proline assessed in Privigen and Hizentra preclinical and clinical studies, and subsequent implications for patients with defects in proline metabolism. Clinical data indicate that proline does not accumulate after Privigen or Hizentra treatment and is not associated with adverse events. There is no evidence to suggest that patients with defects of proline metabolism would be affected by transient elevations in plasma proline following Privigen and/or Hizentra treatment.

AB - Privigen ® (immune globulin intravenous [human], 10% liquid) and Hizentra ® (immune globulin subcutaneous [human], 20% liquid) are stabilized by proline. The clinical implications of administering proline-containing immunoglobulin products to patients with defects of proline metabolism have not been addressed; Privigen and Hizentra are contraindicated in these patients. Some patients with chromosome 22q11.2 deletion syndrome have elevated proline levels; however, only 3-4% of patients also have an immunodeficiency that requires IgG therapy. This review summarizes the evidence related to the safety and pharmacokinetics of proline assessed in Privigen and Hizentra preclinical and clinical studies, and subsequent implications for patients with defects in proline metabolism. Clinical data indicate that proline does not accumulate after Privigen or Hizentra treatment and is not associated with adverse events. There is no evidence to suggest that patients with defects of proline metabolism would be affected by transient elevations in plasma proline following Privigen and/or Hizentra treatment.

KW - 22q11.2 deletion syndrome

KW - hyperprolinemia

KW - intravenous immunoglobulin

KW - pharmacokinetics

KW - proline

KW - proline metabolism

KW - safety

KW - subcutaneous immunoglobulin

UR - http://www.scopus.com/inward/record.url?scp=84856619473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856619473&partnerID=8YFLogxK

U2 - 10.1586/eci.11.97

DO - 10.1586/eci.11.97

M3 - Article

C2 - 22288455

AN - SCOPUS:84856619473

VL - 8

SP - 169

EP - 178

JO - Expert Review of Clinical Immunology

JF - Expert Review of Clinical Immunology

SN - 1744-666X

IS - 2

ER -